Cas:930112-00-8 5-hydroxy-1-(4-methylphenyl)sulfonylindole-3-carboxylic acid manufacturer & supplier

Chemical Name:5-hydroxy-1-(4-methylphenyl)sulfonylindole-3-carboxylic acid

CAS.NO:930112-00-8

Synonyms:5-Hydroxy-1-tosyl-1H-indole-3-carboxylic acid

Molecular Formula:C₁₆H₁₃NO₅S

Molecular Weight:331.34300

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:104.98000

Exact Mass:331.05100

LogP:3.67130

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-Hydroxy-1-tosyl-1H-indole-3-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Hydroxy-1-tosyl-1H-indole-3-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Hydroxy-1-tosyl-1H-indole-3-carboxylic acid Use and application,5-Hydroxy-1-tosyl-1H-indole-3-carboxylic acid technical grade,usp/ep/jp grade.

Related News: Roche too has been riding high on the stock exchange this week, as investors still hope its more extensive Alzheimer’s profile could come good. 5-hydroxy-1-(4-methylphenyl)sulfonylindole-3-carboxylic acid manufacturer This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. 5-hydroxy-1-(4-methylphenyl)sulfonylindole-3-carboxylic acid supplier A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. 5-hydroxy-1-(4-methylphenyl)sulfonylindole-3-carboxylic acid vendor This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. 5-hydroxy-1-(4-methylphenyl)sulfonylindole-3-carboxylic acid factory A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns.